Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | DDT | P30046 | 1/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDM6B | O15054 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 2/20 | 0.45 |
| ▸ | KDM5C | P41229 | 2/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558442 | 1.00 | KEAP1 (0.55) | KEAP1HPGDSKMOL3MBTL1NPC1 | |
| SCHEMBL6573037 | 0.86 | PRKCI (0.50) | HPGDSNPC1RAB9AGLRA3GLRB | |
| SCHEMBL9507238 | 0.86 | BRD4 (0.48) | HPGDSGLRA3GLRB | |
| SCHEMBL6433748 | 0.86 | HPGDS (0.47) | KEAP1HPGDSKMOL3MBTL1NPC1 | |
| SCHEMBL6438972 | 0.84 | HPGDS (0.47) | KEAP1HPGDSNPC1RAB9AKDM4E | |
| SCHEMBL24933996 | 0.82 | ALDH1A1 (0.47) | HPGDSNPC1RAB9AKDM4EGLRA3 | |
| SCHEMBL30999881 | 0.82 | ALDH1A1 (0.47) | HPGDSNPC1RAB9AKDM4EGLRA3 | |
| SCHEMBL24934252 | 0.82 | CDK8 (0.49) | HPGDSNPC1RAB9AKDM4CHDAC6 | |
| SCHEMBL6434655 | 0.82 | GLRA3 (0.62) | HPGDSNPC1RAB9AKDM4CKDM4E | |
| SCHEMBL3964365 | 0.80 | HPGDS (0.58) | HPGDSLTA4HGLRA3GLRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | INDIVIOR UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3212637-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | Indivior UK Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| CN-1662510-A | Process for the preparation of 5- (1, 3-oxazol-2-yl) benzoic acid derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1662510-A | Process for the preparation of 5- (1, 3-oxazol-2-yl) benzoic acid derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-31 | — | — | CN | disclosed |
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-0297804-B1 | SILVER HALIDE PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | KONICA CORPORATION (JP) | 1993-08-18 | — | — | EP | disclosed |
| US-4863846-A | SULFUR | KONICA CORPORATION (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0297804-A2 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | DRD3, DRD2, DRD4 | KEAP1 3601/4885HPGDS 1305/4885KMO 847/4885 |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | KEAP1 3558/4885HPGDS 1419/4885KMO 849/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | KEAP1 3558/4885HPGDS 1419/4885KMO 849/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3654/4885HPGDS 1314/4885KMO 546/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | KEAP1 3558/4885HPGDS 1419/4885KMO 849/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | KEAP1 3558/4885HPGDS 1419/4885KMO 849/4885 |
| US-10239870-B2 | Dopamine D3 receptor antagonists | DRD3, DRD2, DRD4 | KEAP1 3601/4885HPGDS 1305/4885KMO 847/4885 |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | KEAP1 253/4885HPGDS 1766/4885KMO 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.